← Eichor
Condition: Age Macular Degeneration Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Age Macular Degeneration

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial
Phase N/A · 7 location(s) · Medical University of Vienna · NCT06351657The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Populati
Phase N/A · 1 location(s) · Ain Shams University · NCT06755372Defining Retinal Structures Using Hyperspectral Retinal Imaging
NA · 1 location(s) · Center for Eye Research Australia · NCT07555574The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
EARLY_Phase 1 · 1 location(s) · MCPHS University · NCT06593405Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Shanghai Refreshgene Technology Co., Ltd. · NCT06141460A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Phase 2 · 1 location(s) · Innovent Biologics Technology Limited (Shanghai R&D Center) · NCT07275840Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374MMP-9 Inhibition for Recalcitrant Wet AMD
Phase 2 · 1 location(s) · University of Iowa · NCT04504123Lutein, Zeaxathin, and Fish Oil Supplementation
NA · 1 location(s) · Texas A&M University · NCT06489873Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geog
Phase 1/Phase 2 · 5 location(s) · AbbVie · NCT07160179Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation
Phase N/A · 2 location(s) · Singapore National Eye Centre · NCT07653269Progression of Early Atrophic Lesions
Phase N/A · 1 location(s) · University of Utah · NCT05959005A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Phase N/A · 1 location(s) · Guangzhou Jiayin Biotech Ltd · NCT06859515A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participant
Phase 3 · 36 location(s) · Amgen · NCT07614776Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment
NA · 1 location(s) · Fondazione G.B. Bietti, IRCCS · NCT07500324Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Mac
NA · 13 location(s) · VisionCare, Inc. · NCT04796545Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 1 · 2 location(s) · Benobio Co., Ltd. · NCT05803785Gene Therapy(FT-003) for Wet AMD
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492863Phase 1 Study of C.001 in Retinal Degeneration
Phase 1 · 1 location(s) · Cellio Therapeutics Inc · NCT07594236(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NA · 6 location(s) · Carl Zeiss Meditec-Dublin CoCe · NCT07680244A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic
Phase 1/Phase 2 · 1 location(s) · Bionic Sight LLC · NCT07158775Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Pla
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05706896A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Phase N/A · 65 location(s) · Astellas Pharma Global Development, Inc. · NCT06779773Cell Collection to Study Eye Diseases
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT01432847Progression Suppression and Retinal Regression in VEGF-resistant AMD
NA · 1 location(s) · PharmaBio Corporation · NCT07005323QA108 Phase III Study in Subjects With Intermediate AMD
Phase 3 · 1 location(s) · Smilebiotek Zhuhai Limited · NCT07189169Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a M
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT03577041Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Phase 2 · 57 location(s) · ONL Therapeutics · NCT06659445A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy
Phase 1/Phase 2 · 3 location(s) · Theratocular Biotek Co. · NCT07668804
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.